Lawrence Fong

Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1

Edgar G. Engleman, E. Engleman, L. Fong, 2001, The Journal of Immunology.

Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy

E. Small, B. Rini, R. Hershberg, 2006, Cancer.

Cancer Immunotherapy Principles and Practice

Ke Liu, Pedro Romero, Patricia A. Young, 2018 .

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

Mark M. Davis, Edgar G. Engleman, E. Engleman, 2001, Proceedings of the National Academy of Sciences of the United States of America.

A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

Benjamin M Yeh, Lee-may Chen, Yong Huang, 2009, Clinical Cancer Research.

Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells

Hua Su, Chih-Yang Wang, Daniel L. Cooke, 2017, Oncotarget.

Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

Antoni Ribas, Malek Faham, A. Ribas, 2014, Science Translational Medicine.

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

N. Shastri, J. Allison, N. Greenberg, 2008, Proceedings of the National Academy of Sciences.

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

Mario Roederer, Mark M. Davis, S. Swetter, 1999, Nature Medicine.

Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer

Li Zhang, Christopher Kane, Matthew R Cooperberg, 2016, Cancer Immunology Research.